ArticleCancer cell international2026
Limb-bud and heart (LBH) promotes expansion and survival of esophageal adenocarcinoma cells.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEsophageal Adenocarcinoma (EAC) is an aggressive malignancy with poor prognosis. The rising incidence of EAC in the past few decades underscores the need to better understand the molecular features of EAC. The role of the transcriptional co-factor Limb-Bud and Heart (LBH), implicated in embryonic development and Wnt signaling, remains unclearly characterized in gastrointestinal cancers. Given the importance of gastroesophageal reflux disease and acidic bile salts (ABS) exposure in EAC tumorigenesis and progression, we investigated the role of LBH in EAC carcinogenesis. HYPOTHESIS/
objectivesWe hypothesized that LBH promotes tumor progression in EAC by enhancing proliferation and survival, particularly under reflux-like conditions.
methodsLBH expression levels were compared between normal and EACs using publicly available databases, patient samples, and cell lines. Functional roles were assessed using siRNA knockdown and overexpression models in EAC cell lines, followed by BrdU incorporation, colony formation, luciferase reporter assays, qRT-PCR, and western blot analysis of pathway markers.
resultsLBH expression was significantly elevated in EAC tissues and cell lines compared to non-neoplastic esophageal tissues. Knockdown of LBH reduced proliferation, viability, and colony formation, while overexpression had opposite effects. BrdU assays confirmed decreased proliferation with knockdown and increased proliferation with overexpression. Mechanistically, LBH upregulated the Wnt signaling pathway. LBH depletion suppressed β-catenin, cyclin D1, and Wnt transcriptional activity, while overexpression induced activation of these pathways. ABS treatment induced β-catenin and cyclin D1 expression and increased Wnt activity, and these effects were diminished with LBH knockdown. At the transcriptional level, LBH depletion decreased mRNA expression of proliferation-associated markers (PCNA, FOXM1, and CCND1), confirming its role in driving tumor growth. Importantly, LBH knockdown also induced apoptosis and suppressed cell survival signaling. Western blot analysis showed decreased BCL-xL and BCL2 levels with increased PARP cleavage. Similarly qRT-PCR showed reduced BCL2 and BCL-xL, and increased BIM, consistent with heightened apoptosis and reduced survival.
conclusionLBH plays an important role in activation of signaling pathways that promote cell proliferation and survival in EAC. These findings warrant further investigation for testing the therapeutic potential of targeting LBH in EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.